Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors
ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 /PRNewswire/ -- Ichnos Glenmark Innovation, Inc. (IGI), a...